Effectiveness of Bifidobacterium lactis HN019 in Managing Functional Constipation
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 11th, 2024
|
Research has demonstrated that the gut microbiome plays a crucial role in regulating gastrointestinal function. Bifidobacterium animalis subsp lactis HN019, a commensal probiotic, has shown potential in modulating bowel function. A recent study, published in the Journal of the American Medical Association, evaluated the efficacy of Bifidobacterium lactis HN019 in managing constipation.
The clinical trial, conducted in China, included 229 participants diagnosed with functional constipation according to the Rome III criteria but otherwise healthy. The average frequency of complete spontaneous bowel movements in the group was approximately 0.77 events per week. Baseline stool consistency, measured using the Bristol scale, had an average score of around 3. Participants were randomly assigned to receive either a placebo or freeze-dried Bifidobacterium lactis HN019 suspended in maltodextrin and silicon dioxide. The probiotic was initially administered at 7 billion CFU per day, which was reduced to 4.69 billion CFU per day for the remaining eight weeks. The researchers found no significant difference in the frequency of complete spontaneous bowel movements between the groups, indicating that Bifidobacterium lactis HN019 supplementation did not alleviate constipation. Additionally, the probiotic had no effect on stool consistency or fecal moisture levels.
The clinical trial, conducted in China, included 229 participants diagnosed with functional constipation according to the Rome III criteria but otherwise healthy. The average frequency of complete spontaneous bowel movements in the group was approximately 0.77 events per week. Baseline stool consistency, measured using the Bristol scale, had an average score of around 3. Participants were randomly assigned to receive either a placebo or freeze-dried Bifidobacterium lactis HN019 suspended in maltodextrin and silicon dioxide. The probiotic was initially administered at 7 billion CFU per day, which was reduced to 4.69 billion CFU per day for the remaining eight weeks. The researchers found no significant difference in the frequency of complete spontaneous bowel movements between the groups, indicating that Bifidobacterium lactis HN019 supplementation did not alleviate constipation. Additionally, the probiotic had no effect on stool consistency or fecal moisture levels.